dc.contributor.author | Gemici, Aliihsan | |
dc.contributor.author | Özkalemkaş, Fahir | |
dc.contributor.author | Doğu, Mehmet Hilmi | |
dc.contributor.author | Tekinalp, Atakan | |
dc.contributor.author | Alacacıoğlu, İnci | |
dc.contributor.author | Güney, Tekin | |
dc.contributor.author | İnce, İdris | |
dc.contributor.author | Gedük, Ayfer | |
dc.contributor.author | Akgün Çağlıyan, Gülsüm | |
dc.contributor.author | Maral, Senem | |
dc.contributor.author | Serin, İstemi | |
dc.contributor.author | Gündüz, Eren | |
dc.contributor.author | Karakuş, Volkan | |
dc.contributor.author | Beköz, Hüseyin Saffet | |
dc.contributor.author | Eren, Rafet | |
dc.contributor.author | Pınar, İbrahim Ethem | |
dc.contributor.author | Güneş, Ahmet Kürşad | |
dc.contributor.author | Sargın, Fatma Deniz | |
dc.contributor.author | Sevindik, Ömür Gökmen | |
dc.date.accessioned | 2021-08-26T07:13:32Z | |
dc.date.available | 2021-08-26T07:13:32Z | |
dc.date.issued | 2021 | en_US |
dc.identifier.citation | Gemici, A., Özkalemkaş, F., Doğu, M. H., Tekinalp, A., Alacacıoğlu, İ., Güney, T. ... Sevindik, Ö. G. (2021). A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia. Clinical Lymphoma, Myeloma & Leukemia, 21(8), E686-E692. https://dx.doi.org/10.1016/j.clml.2021.04.004 | en_US |
dc.identifier.issn | 2152-2650 | |
dc.identifier.issn | 2152-2669 | |
dc.identifier.uri | https://dx.doi.org/10.1016/j.clml.2021.04.004 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/7984 | |
dc.description.abstract | Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients with a median age of 67 years from different centers were included in the final analysis. Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.
Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML. Materials and Methods: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML. Results: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported. Conclusion: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | CIG Media Group | en_US |
dc.rights | info:eu-repo/semantics/embargoedAccess | en_US |
dc.subject | Bcl2 | en_US |
dc.subject | Inhibitor | en_US |
dc.subject | Venetoclax | en_US |
dc.subject | Acute Myeloid Leukemia | en_US |
dc.subject | Real Life | en_US |
dc.title | A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Clinical Lymphoma, Myeloma & Leukemia | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-3385-8359 | en_US |
dc.authorid | 0000-0003-1237-8281 | en_US |
dc.authorid | 0000-0001-9636-4113 | en_US |
dc.identifier.volume | 21 | en_US |
dc.identifier.issue | 8 | en_US |
dc.identifier.startpage | E686 | en_US |
dc.identifier.endpage | E692 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1016/j.clml.2021.04.004 | en_US |
dc.identifier.wosquality | Q3 | en_US |
dc.identifier.scopusquality | Q2 | en_US |